Schonfeld Strategic Advisors’s Contineum Therapeutics CTNM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Buy	+69,441	New	+$910K	﹤0.01%	1408
2026 Q1	–	Sell	-22,673	Closed	-$259K	–	2762
2025 Q4	$259K	Buy	22,673 +4,177	+23%	+$47.7K	﹤0.01%	1623
2025 Q3	$217K	Sell	18,496 -145,628	-89%	-$1.17M	﹤0.01%	1923
2025 Q2	$652K	Buy	164,124 +21,924	+15%	+$95.3K	﹤0.01%	1457
2025 Q1	$993K	Buy	142,200 +16,205	+13%	+$147K	0.01%	1299
2024 Q4	$1.85M	Buy	+125,995	New	+$2M	0.01%	870

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Schonfeld Strategic Advisors's CTNM Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 69,441 shares worth $1.14M. The stake represents ﹤0.01% of the portfolio and ranks #1408 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in CTNM as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in CTNM in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.85M in Q4 2024. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Schonfeld Strategic Advisors held 69,441 shares of Contineum Therapeutics worth $1.14M as of Q2 2026.
Contineum Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
Contineum Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1408 holding.
Schonfeld Strategic Advisors first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 6 quarters since.
Schonfeld Strategic Advisors's Contineum Therapeutics position peaked at $1.85M in Q4 2024.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.